Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) has appointed Tal Parnes as the new chairman of the board, effective February 1, 2025. Parnes, who has served as an independent director since July 2021, brings over 30 years of experience in technology, particularly in medical technology and pharmaceuticals. He succeeds Prof. Benad Goldwasser, who resigned for personal reasons.

Parnes' background includes co-founding and serving as CEO of Zuta-Core and HQL Pharmaceuticals , along with executive roles at several technology companies. The appointment aims to enhance Inspira's leadership and market position.

The company recently achieved significant milestones with its INSPIRA ART100 system receiving FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in June and July 2024.

Positive

• FDA 510(k) clearance obtained for INSPIRA ART100 system
• Israeli AMAR certification received for multiple procedures
• New chairman brings 30+ years of relevant industry experience
• Previous board experience with company since July 2021

Negative

• None.

RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.

 

 

Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision.

As a serial entrepreneur, Parnes has demonstrated his ability to drive innovation and growth across various high-tech sectors, including medical technology, communications and defense. Mr. Parnes is familiar with the Company and its technology, having served as an independent director of the Company since July 2021.

Mr. Parnes is a veteran executive in the medical technology industry. He co-founded and is the former chief executive officer and president at Zuta-Core Ltd. and HQL Pharmaceuticals Ltd. Mr. Parnes also served as chief operating officer at Silynx Communications Inc. as a vice president of operations at Wavion Inc. and Atrica Ltd. He also served as chief financial officer and director of business development of Printlife Ltd.

The appointment of Mr. Parnes as chairman of the board of directors will enhance the Company's leadership. Mr. Parnes' unwavering commitment to integrating his vast knowledge of emerging technologies and market trends will be invaluable. Mr. Parnes' leadership will not only refine the Company's strategic vision but also bolster the Company's competitive advantage in the market, positioning the Company for sustainable success in the future. The Company is eager to harness Mr. Parnes' insights and experience as the Company reaches new heights.

The Company would like to thank Prof. Benad Goldwasser, MD, for his leadership role as chairman of the board of directors since 2021. The Company extends its gratitude for his numerous activities and contributions to the Company, spanning business, medical, and administrative aspects. Prof. Goldwasser provided invaluable support during the Company's Nasdaq Capital Market listing and leveraged his extensive network of connections from his years of experience. The Company accepted Prof. Goldwasser's resignation from his position, which was  due to personal reasons.

 

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake during treatment. The INSPIRA ART is being equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions.

In June and July 2024, respectively, the Company's INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans nor approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential positive outcome of Mr. Parnes' appointment. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Photo - https://mma.prnewswire.com/media/2602501/Tal_Parnes.jpg
Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inspira-announces-the-appointment-of-tal-parnes-as-the-new-chairman-of-the-board-bringing-vast-experience-in-the-medical-technology-and-pharmaceutical-sectors-302356143.html

SOURCE Inspira Technologies

FAQ

When will Tal Parnes begin his role as chairman of IINN?

Tal Parnes will begin his role as chairman of Inspira Technologies (IINN) effective February 1, 2025.

What regulatory approvals has IINN's INSPIRA ART100 system received in 2024?

In 2024, IINN's INSPIRA ART100 system received FDA 510(k) clearance for CBP procedures in June and Israeli AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in July.

What is Tal Parnes' previous experience with IINN?

Tal Parnes has served as an independent director of Inspira Technologies (IINN) since July 2021.

Why did the previous IINN chairman step down?

Prof. Benad Goldwasser stepped down as chairman of IINN due to personal reasons.

What is the market potential for IINN's INSPIRA ART technology?

IINN's INSPIRA ART technology targets the $19 billion mechanical ventilation market, with potential to serve 20 million ICU patients with acute respiratory failure annually.